Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study
Suresh Senan, Isamu Okamoto, Gyeong won Lee, Yuanbin Chen, Seiji Niho, Gabriel Mak, Wenliang Yao, Norah Shire, Haiyi Jiang, Byoung Chul Cho
Dive into the research topics of 'Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study'. Together they form a unique fingerprint.